Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.

Simsek S, de Galan BE.

Curr Opin Lipidol. 2012 Dec;23(6):540-7. doi: 10.1097/MOL.0b013e3283590b8f. Review.

PMID:
23160401
[PubMed - indexed for MEDLINE]
2.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
[PubMed - indexed for MEDLINE]
3.

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.

Chrysant SG, Chrysant GS.

Am J Cardiol. 2012 Jun 1;109(11):1681-5. doi: 10.1016/j.amjcard.2012.01.398. Epub 2012 Mar 16. Review.

PMID:
22425330
[PubMed - indexed for MEDLINE]
4.

Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.

Xiao C, Dash S, Lewis GF.

Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):289-94. Review.

PMID:
22827289
[PubMed - indexed for MEDLINE]
5.

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.

van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M.

Diabetes Obes Metab. 2013 Jul;15(7):593-606. doi: 10.1111/dom.12050. Epub 2013 Jan 21. Review.

PMID:
23216746
[PubMed - indexed for MEDLINE]
6.

Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.

Grigoropoulou P, Eleftheriadou I, Zoupas C, Diamanti-Kandarakis E, Tentolouris N.

Curr Diabetes Rev. 2013 Sep;9(5):412-7. Review.

PMID:
23855508
[PubMed - indexed for MEDLINE]
7.

Cardiovascular biology of the incretin system.

Ussher JR, Drucker DJ.

Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8. Review.

PMID:
22323472
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Recent advances in incretin-based therapies.

Russell-Jones D, Gough S.

Clin Endocrinol (Oxf). 2012 Oct;77(4):489-99. doi: 10.1111/j.1365-2265.2012.04483.x. Review.

PMID:
22804841
[PubMed - indexed for MEDLINE]
9.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
[PubMed - indexed for MEDLINE]
10.

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.

Neumiller JJ.

Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):276-88. Review.

PMID:
22827291
[PubMed - indexed for MEDLINE]
11.

Incretin-based therapies and cardiovascular risk.

Mannucci E, Dicembrini I.

Curr Med Res Opin. 2012 May;28(5):715-21. doi: 10.1185/03007995.2012.678940. Epub 2012 Apr 13. Review.

PMID:
22439700
[PubMed - indexed for MEDLINE]
12.

[Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].

Winkler G.

Orv Hetil. 2013 Feb 17;154(7):248-55. doi: 10.1556/OH.2013.29553. Review. Hungarian.

PMID:
23395788
[PubMed - indexed for MEDLINE]
13.

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Drab SR.

Pharmacotherapy. 2010 Jun;30(6):609-24. doi: 10.1592/phco.30.6.609. Review.

PMID:
20500049
[PubMed - indexed for MEDLINE]
14.

Potential cardiovascular effects of incretin-based therapies.

Deacon CF, Marx N.

Expert Rev Cardiovasc Ther. 2012 Mar;10(3):337-51. doi: 10.1586/erc.12.5. Review.

PMID:
22390806
[PubMed - indexed for MEDLINE]
15.

Incretin-based therapies for type 2 diabetes mellitus.

Lovshin JA, Drucker DJ.

Nat Rev Endocrinol. 2009 May;5(5):262-9. doi: 10.1038/nrendo.2009.48. Review.

PMID:
19444259
[PubMed - indexed for MEDLINE]
16.

[The value of incretin based therapies].

Gallwitz B.

Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Review. German. No abstract available.

PMID:
19421931
[PubMed - indexed for MEDLINE]
17.

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.

McGill JB.

Postgrad Med. 2009 Jan;121(1):46-58. doi: 10.3810/pgm.2009.01.1954.

PMID:
19179813
[PubMed - indexed for MEDLINE]
18.

Incretin-based therapies.

Stonehouse AH, Darsow T, Maggs DG.

J Diabetes. 2012 Mar;4(1):55-67. doi: 10.1111/j.1753-0407.2011.00143.x. Review.

PMID:
21707956
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.

Cariou B.

Diabetes Metab. 2012 Oct;38(4):298-308. doi: 10.1016/j.diabet.2012.04.003. Epub 2012 Jun 4. Review.

PMID:
22672960
[PubMed - indexed for MEDLINE]
Free Article
20.

New developments in incretin-based therapies: the current state of the field.

Robertson C.

J Am Acad Nurse Pract. 2009 Nov;21 Suppl 1:631-41. Review.

PMID:
19900194
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk